Strategic collaborations that can help build market share and enhance revenue streams
Assertio is currently involved in two forms of strategic partnerships:
- Commercialization partnerships — Out-licensing internally developed drugs to commercialization partners worldwide (often while retaining rights in selected countries/market segments)
- Development and commercialization partnerships — Collaborating with companies looking to use Acuform® technology to enhance their own pharmaceutical products
Current development and commercialization partnerships
|A commercialization agreement was signed in December 2017 for the U.S. commercialization rights to NUCYNTA® ER and NUCYNTA® for the management of pain.|
|A licensing agreement was established in July 2011 granting Ironwood worldwide rights to Acuform technology for the development of IW3718 for the potential treatment of refractory gastroesophageal reflux disease (GERD).|
|A license agreement was established in March 2011 granting Boehringer Ingelheim worldwide rights to Acuform technology for the development and commercialization of certain fixed-dose combination products including extended-release metformin and proprietary Boehringer Ingelheim compounds in development for type 2 diabetes.|
|A license and development agreement was established in November 2008 granting Mallinckrodt an option to license Acuform technology to develop and commercialize up to four pharmaceutical products.|
|A license agreement was established in August 2010 granting Janssen Pharmaceutica worldwide rights to Acuform technology for the development of a fixed-dose combination formulation of canagliflozin (a SGLT2 inhibitor) and extended-release metformin.|
To learn more, visit the News Releases section of this website.
Assertio welcomes inquiries from companies interested in partnering. Contact us at firstname.lastname@example.org.